Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 3Not yet recruiting 3Recruiting 2Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 1Breast 1

Conditions

Chemotherapy-Induced Thrombocytopenia 1Breast Neoplasms 1

Interventions

Cyclophosphamide 1488Cisplatin 1410Paclitaxel 1316Radiotherapy 1259Carboplatin 1247Gemcitabine 1214Docetaxel 1110Bevacizumab 1029Fluorouracil 894Doxorubicin 786Dexamethasone 746Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 673Etoposide 673Irinotecan 634Filgrastim 621Cytarabine 584Leucovorin 578Nivolumab 557Vincristine 510Prednisone 474Cetuximab 464Bortezomib 457Erlotinib Hydrochloride 456Trastuzumab 448Methotrexate 437Lenalidomide 426Pemetrexed 419

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Interventional × hetrombopag × Clear all
NCT05394285 2026-04-06

A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Anti-tumor Treatment in Advanced Breast Cancer

Henan Cancer Hospital

Phase 2 Completed
60 enrolled
Breast

Breast Neoplasms

NCT03976882 2025-05-16

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
129 enrolled
Classical hematology

Chemotherapy-Induced Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡